Search | Clinical Trials Finder

Conditions: Schizophrenia
Interventions: Lu AF35700, Placebo; Drug
Lead sponsor: H. Lundbeck A/S; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2013
U.S. locations: 1
States / cities: Glendale, California

Conditions: Small Cell Lung Cancer
Interventions: Pembrolizumab 200 mg, Pembrolizumab 400 mg, Pembrolizumab placebo (saline), Olaparib 300 mg BID, Olaparib matching placebo, Etoposide 100 mg/m^2, Platinum, investigator's choice, Standard Thoracic Radiotherapy, Prophylactic Cranial Irradiation (PCI); Biological · Drug · Radiation
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 672 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 35
States / cities: Chandler, Arizona • Loma Linda, California • Washington D.C., District of Columbia + 29 more

Conditions: Diabetic Nephropathy, Chronic Kidney Disease
Interventions: Zemplar (paricalcitol) capsules, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 20 Years and older
Enrollment: 281 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 27
States / cities: Phoenix, Arizona • Fountain Valley, California • Yuba City, California + 21 more

Conditions: Lupus Nephritis
Interventions: Mycophenolate Mofetil/Mycophenolic Acid, Obinutuzumab, Placebo, Methylprednisolone, Prednisone; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 126 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 7
States / cities: La Jolla, California • Palo Alto, California • Atlanta, Georgia + 4 more

Conditions: Major Depressive Disorder, Healthy Volunteer
Interventions: Basimglurant, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Garden Grove, California

Conditions: Huntington Disease, Chorea
Interventions: atomoxetine, Matching Placebo; Drug
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Insulin Sensitivity, Lipid Metabolism, Resistant Starch, Potato
Interventions: Potato (Resistant Starch), CHO-matched (Low-fiber, RS-free); Other
Lead sponsor: Midwest Center for Metabolic and Cardiovascular Research; Other
Eligibility: 18 Years to 74 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Boca Raton, Florida

Conditions: Diabetes Mellitus, Type 2, Non-Alcoholic Fatty Liver Disease
Interventions: BFKB8488A, Placebo; Drug · Other
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 17
States / cities: Anniston, Alabama • Coronado, California • Stanford, California + 12 more

Conditions: Generalized Myasthenia Gravis
Interventions: Iptacopan, Matching Placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 146 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2032
U.S. locations: 13
States / cities: Scottsdale, Arizona • Fullerton, California • Sacramento, California + 10 more

Conditions: Bladder, Neurogenic
Interventions: tamsulosin hydrochloride, Placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 2 Years to 16 Years
Enrollment: 231 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 7
States / cities: Los Angeles, California • Tampa, Florida • St Louis, Missouri + 4 more

Conditions: Chronic Fatigue Syndrome, Myalgic Encephalomyelitis
Interventions: Solriamfetol Oral Tablet [Sunosi], Placebo; Drug
Lead sponsor: Rochester Center for Behavioral Medicine; Other
Eligibility: 18 Years to 75 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Rochester Hills, Michigan

Conditions: Atherosclerotic Cardiovascular Disease, Metabolic Syndrome
Interventions: Health Education, Transcendental Meditation; Behavioral
Lead sponsor: Robert Schneider, MD; Other
Eligibility: 55 Years and older · Female only
Enrollment: 201 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 2
States / cities: Washington D.C., District of Columbia • Atlanta, Georgia

Conditions: Fibrosis, Skin Scarring, Skin Wound, Hypertrophic Scar, Scar, Keloid
Interventions: LED-RL phototherapy, Mock irradiation; Device
Lead sponsor: State University of New York - Downstate Medical Center; Other
Eligibility: Not listed
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Brooklyn, New York

Conditions: Mild Cognitive Impairment, Prodromal Alzheimer's Disease
Interventions: Placebo Oral Tablet, AGB101 220 mg tablet; Drug
Lead sponsor: AgeneBio; Industry
Eligibility: 55 Years to 85 Years
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 23
States / cities: Phoenix, Arizona • Laguna Hills, California • Oceanside, California + 20 more

Conditions: Bipolar Disorder, Depression
Interventions: Cariprazine, Placebo; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 493 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 42
States / cities: Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 37 more

Conditions: Major Depressive Disorder
Interventions: Placebo, Vilazodone; Drug
Lead sponsor: Forest Laboratories; Industry
Eligibility: 12 Years to 17 Years
Enrollment: 529 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2016
U.S. locations: 52
States / cities: Imperial, California • Los Angeles, California • Murrieta, California + 46 more

Conditions: Rheumatoid Arthritis
Interventions: Filgotinib, Placebo to match filgotinib, csDMARDs; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years and older
Enrollment: 449 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 55
States / cities: Huntsville, Alabama • Gilbert, Arizona • Covina, California + 52 more

Conditions: Focal Epilepsy
Interventions: BHV-7000, Placebo; Drug
Lead sponsor: Biohaven Therapeutics Ltd.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 390 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 49
States / cities: Phoenix, Arizona • Tucson, Arizona • Little Rock, Arkansas + 44 more

Conditions: Depressive Disorder, Major, Anhedonia
Interventions: Aticaprant, Placebo; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 46
States / cities: Tucson, Arizona • Anaheim, California • Culver City, California + 37 more

Conditions: Systolic Hypertension
Interventions: LCZ696, Valsartan, AHU377, Placebo; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 910 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 19
States / cities: Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more

Conditions: Autism Spectrum Disorder (ASD)
Interventions: Placebo, RO7017773; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 15 Years to 45 Years
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 11
States / cities: Phoenix, Arizona • New Haven, Connecticut • Orlando, Florida + 8 more

Conditions: ADHD
Interventions: methylphenidate transdermal system, Placebo; Drug
Lead sponsor: Noven Therapeutics; Industry
Eligibility: 13 Years to 17 Years
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 32
States / cities: Scottsdale, Arizona • Lafayette, California • Wildomar, California + 29 more

Conditions: HIV-associated Enteropathy
Interventions: Serum-derived bovine immunoglobulin protein isolate (SBI), Placebo; Other
Lead sponsor: Entera Health, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 10
States / cities: Los Angeles, California • Sacramento, California • San Francisco, California + 7 more

Conditions: Type 2 Diabetes Mellitus
Interventions: SAR425899, Placebo, Liraglutide, Metformin; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 296 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 23
States / cities: Sheffield, Alabama • Huntington Park, California • Los Angeles, California + 18 more

Search by objective public record fields.

Safety and Tolerability Study of Lu AF35700 After Repeated Dosing in Patients With Schizophrenia

Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)

The Effect of Paricalcitol Capsules on Reducing Albuminuria in Patients With Type 2 Diabetic Nephropathy Being Treated With Renin-angiotensin System Inhibitors

A Study to Evaluate the Safety and Efficacy of Obinutuzumab Compared With Placebo in Participants With Lupus Nephritis (LN)

A Study of the Safety, Tolerability, and Pharmacokinetics of Multiple-Ascending Dose Basimglurant in Healthy Subjects and in Patients With Major Depressive Disorder (MDD)

Atomoxetine and Huntington's Disease

Effects of Potato Resistant Starch Intake on Insulin Sensitivity, Related Metabolic Markers and Satiety

A Multiple Ascending Dose Study to Evaluate Safety and Tolerability of BFKB8488A in Participants With Type 2 Diabetes Mellitus and Participants With Non-Alcoholic Fatty Liver Disease

A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.

Study to Evaluate the Efficacy and Safety of Tamsulosin in Children With Neurogenic Bladder

A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Multicenter Trial of Meditation and Health Education for Cardiometabolic Disease in Black Women

Light Emitting Diode-Red Light (LED-RL) Phototherapy for Skin Scarring Prevention

Study of AGB101 in Mild Cognitive Impairment Due to Alzheimer's Disease

Study of the Efficacy of a Fixed-dose Regimen of Cariprazine Compared to Placebo for Treatment of the Depressive Episode in Participants With Bipolar I Disorder

Safety and Efficacy of Vilazodone in Adolescent Patients With Major Depressive Disorder

Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment

A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

A 12-Week Placebo-Controlled Study to Investigate the Efficacy, Safety, and Tolerability of RO7017773 in Participants Aged 15-45 Years With Autism Spectrum Disorder (ASD)

Evaluate the Efficacy &Safety of Methylphenidate Transdermal System (MTS) in Adolescents Aged 13-17 Years With ADHD

Impact of SBI, a Medical Food, on Nutritional Status in Patients With HIV-associated Enteropathy

A Study to Assess the Safety and Efficacy of SAR425899 in Patients With Type 2 Diabetes Mellitus